New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events
about
New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolismLimited evidence on persistence with anticoagulants, and its effect on the risk of recurrence of venous thromboembolism: a systematic review of observational studiesReversing the anticoagulation effects of dabigatran.Development and Validation of an Oral Anticoagulation Knowledge Tool (AKT).Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs.New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation.Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population-Based Study.The relationship between knowledge, health literacy, and adherence among patients taking oral anticoagulants for stroke thromboprophylaxis in atrial fibrillation.Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach.Preliminary report: Measurement of apixaban and rivaroxaban in plasma from bleeding patients.New Indications for Dabigatran: A Suggestion from a Drug Use Evaluation Study.Rivaroxaban Use in Patients with Hemoglobinopathies.Engineering a simple lateral flow device for animal blood coagulation monitoring.Italian intersociety consensus on DOAC use in internal medicine.Iatrogenic Spinal Subdural Hematoma due to Apixaban: A Case Report and Review of the Literature.Real-world effectiveness and safety of oral anticoagulation strategies in atrial fibrillation: a cohort study based on a German claims dataset.Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors.The use of Apixaban for the treatment of an LV thrombusAnticoagulation Knowledge Tool (AKT): Further evidence of validity in the Italian populationAssociation between medication adherence and illness perceptions in atrial fibrillation patients treated with direct oral anticoagulants: An observational cross-sectional pilot study
P2860
Q26786574-989BE4C2-BE55-4A3A-9B04-ADE3413B4A8BQ28078824-35AB904E-D94D-4F42-96D9-48C57DD55EA7Q30400249-94C698AC-8870-436B-9D87-4BD3744C76A2Q36063155-93452991-7583-48CA-BC89-D22D62A71024Q38687974-770EA244-E92D-4430-B6E2-AEBEE4A2718DQ39213540-CB9072EB-4C9B-45D0-B180-50A652208EDCQ41524034-8C620E14-1DDF-40EC-84AD-2BE95F2C43D7Q47136340-94CF95A5-2687-4DFD-8DA3-8FD3E9B44946Q48132702-B8F29CF6-89B6-460B-879C-DCAAEF7066E2Q48158928-48237760-480B-4BD1-8DBB-D5A62DAB0193Q48191307-1828120D-7B40-4A1F-B3AA-67169B7C0CDBQ49275825-65DB46E2-1D4B-45D8-90E0-53FCD02214D1Q49817762-C9152D0F-943C-4C57-966D-39E6B0000917Q50048280-4A1550BB-48C4-4407-A31E-E617E22E137DQ50896785-5B94C243-25F3-4B39-AEFA-DD5E42E71ABAQ52579024-CB555331-7BC9-43EE-B2A4-50A1A7FA7134Q54975650-3912CBB0-477A-469B-9EF6-99865560976FQ55272081-61F914F0-F5F4-47D7-8417-523327F91A48Q57279650-C907D2F2-1208-41BB-9377-3CB1E5ABF425Q58783414-6FB231D4-321F-43F2-8000-65991517E4ADQ59126479-BC01F352-9812-43D9-B02B-CBEF77D75F3E
P2860
New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
New oral anticoagulants: their ...... nts with thromboembolic events
@ast
New oral anticoagulants: their ...... nts with thromboembolic events
@en
New oral anticoagulants: their ...... nts with thromboembolic events
@nl
type
label
New oral anticoagulants: their ...... nts with thromboembolic events
@ast
New oral anticoagulants: their ...... nts with thromboembolic events
@en
New oral anticoagulants: their ...... nts with thromboembolic events
@nl
prefLabel
New oral anticoagulants: their ...... nts with thromboembolic events
@ast
New oral anticoagulants: their ...... nts with thromboembolic events
@en
New oral anticoagulants: their ...... nts with thromboembolic events
@nl
P2093
P2860
P921
P3181
P356
P1476
New oral anticoagulants: their ...... nts with thromboembolic events
@en
P2093
Agon Mekaj
Ermira Miftari
Shkelzen Duci
Ymer Mekaj
P2860
P304
P3181
P356
10.2147/TCRM.S84210
P407
P577
2015-06-24T00:00:00Z